Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Baylor College of Medicine Pfizer |
---|---|
Information provided by: | Baylor College of Medicine |
ClinicalTrials.gov Identifier: | NCT00646451 |
Pregabalin is approved for the treatment of nerve pain as well as an additional therapy in the treatment of seizures. In December 2004, Pfizer gained Food and Drug Administration (FDA) approval for use of pregabalin in nerve pain associated with diabetes and shingles; making it the first FDA-approved treatment for both of these nerve pain states.
Tremor is uncontrolled trembling in part of the body. Essential tremor (ET) is associated with purposeful movement(e.g., holding a glass to drink, shaving, writing and buttoning a shirt). It occurs most often in the hands and head and also may affect the arms, voice box (larynx), trunk, and legs. ET is caused by abnormalities in areas of the brain that control movement. It usually does not result in serious complications.
ET affects approximately 5 million people in the United States. Incidence is highest in people over the age of 60.
ET usually develops gradually during middle age or later in life. Symptoms may remain mild or become more severe over time. Stress, fatigue, anxiety, and hot or cold weather can worsen the disorder. Severe tremor may cause difficulty doing activities of daily living, such as:
The purpose of this study is to examine the tolerability and efficacy of Pregabalin in patients with ET .
In other words, can patients diagnosed with ET tolerate high dose of pregabalin? Will the pregabalin be considered as an efficient medicine in the treatment of ET?
Condition | Intervention | Phase |
---|---|---|
Essential Tremor |
Drug: pregabalin Drug: placebo capsules |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A 17 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF PREGABALIN IN ESSENTIAL TREMOR |
Estimated Enrollment: | 20 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Pregabalin 75 mg bid to a maximum dose of 300 mg bid
|
Drug: pregabalin
75 mg bid to 300 mg bid based on per subject tolerability
|
2: Placebo Comparator
Placebo to 4 capsules bid
|
Drug: placebo capsules
up to 4 capsules bid as tolerated
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
PDCMDC 6550 Fannin, Suite 1801 | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Lina Shinawi, CCRC 713-798-5519 lshinawi@bcm.edu | |
Principal Investigator: William G Ondo, MD | |
Sub-Investigator: Joseph Jankovic, MD | |
Sub-Investigator: Joohi Jimenez-Shahed, MD |
Responsible Party: | Baylor College of Medicine ( William G. Ondo, MD ) |
Study ID Numbers: | H-19086 |
Study First Received: | December 28, 2007 |
Last Updated: | March 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00646451 |
Health Authority: | United States: Institutional Review Board |
Essential tremor Activities of Daily Living (ADL's) |
Signs and Symptoms Essential Tremor Movement Disorders Benign essential tremor syndrome Pregabalin |
Central Nervous System Diseases Neurologic Manifestations Dyskinesias Tremor |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases Peripheral Nervous System Agents |
Analgesics Central Nervous System Agents Anticonvulsants Pharmacologic Actions |